Those savings, coupled with increased cash flows, will be important to help Takeda achieve its goal of quickly paying down some of the large debt burden it will take on to pay for the deal.
To pay the cash fraction of the deal, Takeda told that it had acquired a loan facility of $31 billion with Sumitomo Mitsui Banking Corp., JP Morgan Chase Bank NA, and MUFG Bank Ltd., among others.
A fair share of industry watchers initially expected that Takeda wouldn't make it to the finish line since snapping up Shire would mean taking on a hefty debt load. Takeda's main areas of focus moving forward will be neuroscience, oncology, gastroenterology and vaccines.
Takeda expects substantial cost synergies of at least $1.4 billion. Takeda also would get increased exposure to the USA, the world's biggest pharmaceutical market and where Shire generates most of its revenue.
McCarthy & Stone (MCS) Receives GBX 173.83 Average Target Price from Analysts
Hillman Co sold 271,803 shares as Rti Surgical Inc (RTIX)'s stock rose 9.64%. 59 funds opened positions while 95 raised stakes. Danaher Corporation (DHR) formed multiple top with $107.21 target or 7.00% above today's $100.20 share price.
Under the terms of the deal, Shire investors will receive $30.33 in cash and either 0.839 new Takeda shares or 1.678 Takeda ADSs for each share, the companies said. It represents a 60 per cent premium to Shire's closing price on March 27, before Takeda disclosed its interest.
The deal is part of Takeda's strategy of becoming a global pharmaceutical company.
Takeda said the deal will save about US$600 million in duplicated research and development costs.
A completed deal would dwarf SoftBank Group's $40bn purchase of Sprint in 2013, which ranked as the biggest takeover by a Japanese company.
Kane Williamson's steady hand earns Sunrisers Hyderabad final-over IPL win
Bhuvneshwar Kumar, who made a comeback after a back injury kept him out for a few games, had a decent but wicket-less outing. Hales began slowly before opening his shoulders and smashed Avesh Khan for three sixes to nearly double his score.
Takeda, meanwhile, has like many Japanese companies been expanding overseas to compensate for slowing growth at home.
Takeda's bid follows a series of worldwide acquisitions by the Japanese drug-maker as it seeks to make up for a slowing domestic market and take its place on the global stage among the largest pharma firms, including Pfizer.
"Over the last 30 years, Shire has become the global leader in treating rare diseases, delivering innovative products that transform patients' lives", said Shire's chairman Susan Kilsby.
In a statement, Christophe Weber, president and chief executive officer of Takeda, said: "Shire's highly complementary product portfolio and pipeline, as well as experienced employees, will accelerate our transformation for a stronger Takeda." . That deal, Shire said today, is expected to close in the second quarter or third quarter, with the net proceeds meant to be used to repay debt.
Congress agenda only to oppose me, disrupt Parliament: Modi
He added that the Congress party neither cared about the present nor the future of Karnataka, but only about remaining in power. PM Modi also blamed the Congress for "distorting history" as part of a conspiracy to divide the society.